Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

132.44 +1.54 (+1.18%)
Streaming Delayed Price Updated: 12:37 PM EDT, Apr 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Screening For Black Friday Bargains In The Stock Market ↗
 
Via Benzinga
News headline image
For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
News headline image
NASDAQ:NBIX qualifies as a high growth stock and is consolidating. ↗
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
News headline image
NASDAQ:NBIX stands out as a stock that provides good value for the fundamentals it showcases. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is an undervalued gem with solid fundamentals. 
Via Chartmill
News headline image
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio ↗
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience strategy and boosting competition for Cobenfy. 
Via Benzinga
News headline image
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank. ↗
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX. 
Via Chartmill
News headline image
NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move. ↗
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Standout High-Growth Stock in a Consolidation Phase. 
Via Chartmill
News headline image
Decoding 19 Analyst Evaluations For Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
NASDAQ:NBIX, a growth stock which is not overvalued. ↗
Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced. 
Via Chartmill
News headline image
In-Depth Examination Of 20 Analyst Recommendations For Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank. ↗
Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced. 
Via Chartmill
News headline image
NASDAQ:NBIX appears to be flying under the radar despite its strong fundamentals. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
News headline image
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
News headline image
Critical Insights From Neurocrine Biosciences Analyst Ratings: What You Need To Know ↗
 
Via Benzinga
News headline image
"Rule Breaker Investing" Market Cap Game Show: Throwdowns & Long-Term Wins ↗
Motley Fool analysts Matt Argersinger and Yasser El-Shimy face off. 
Via The Motley Fool
News headline image
Despite its growth, NASDAQ:NBIX remains within the realm of affordability. ↗
In the world of growth stocks, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) shines as a value proposition. 
Via Chartmill
News headline image
For those who appreciate value investing, NASDAQ:NBIX is a compelling option with its solid fundamentals. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
News headline image
Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpoint ↗
Neurocrine Biosciences announced that its ERUDITE Phase 2 trial for luvadaxistat failed to meet its primary endpoint in treating cognitive impairment in schizophrenia. The company will halt development... 
Via Benzinga
News headline image
Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio? ↗
10 worst performing large-cap stocks in August: Super Micro, Dollar General, Snap, PDD Holdings, Intel, Tencent Music, Gold Fields, Charles River, Moderna, Neurocrine Biosciences. 
Via Benzinga
News headline image
Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a stock that provides good value for the fundamentals it showcases. 
Via Chartmill
News headline image
Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio? ↗
10 worst performing large-cap stocks in the last week. Dollar General, Super Micro Computer, Okta, Pure Storage, Neurocrine Biosciences among them. 
Via Benzinga
News headline image
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review ↗
The Dow Jones hit a new high while Nvidia led a Nasdaq retreat. 
Via Investor's Business Daily
Topics Stocks
News headline image
Why Neurocrine Biosciences Stock Was Tumbling This Week ↗
The company promises to advance a top investigational drug to late-stage testing, but investors might not think that's a fine idea. 
Via The Motley Fool
News headline image
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock ↗
Neurocrine Biosciences reports positive Phase 2 trial results for NBI-1117568 in adults with schizophrenia, showing significant reduction in PANSS scores with a 20 mg dose. Piper Sandler upgrades the... 
Via Benzinga
News headline image
NVIDIA To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Nasdaq Down Over 1%; Foot Locker Shares Tumble After Q2 Results ↗
 
Via Benzinga
News headline image
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors ↗
Neurocrine Biosciences reports Phase 2 trial results for NBI-1117568 showing significant improvement in schizophrenia symptoms, with an 18.2-point reduction in PANSS scores at a 20 mg dose. 
Via Benzinga
News headline image
US Stocks Mixed; JM Smucker Slashes Annual Guidance ↗
 
Via Benzinga
News headline image
Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers ↗
As new schizophrenia drugs move toward approval, Neurocrine Biosciences reports a subpar outcome for its phase 2 trial. 
Via Investor's Business Daily
News headline image
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna ↗
Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomberg reports. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.